Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$489.24 USD

489.24
352,810

-5.02 (-1.02%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $486.00 -3.24 (-0.66%) 5:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Idexx Laboratories (IDXX) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 4.38% and -1.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?

by Zacks Equity Research

In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Earnings Surprise Streak Could Continue for Idexx (IDXX)

by Zacks Equity Research

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS

Tirthankar Chakraborty headshot

4 Stocks to Make the Most of the Growing Love for Pets

by Tirthankar Chakraborty

With the U.S. pet industry poised to grow 3.9% to a record $75.4 billion this year, here are few stocks that could gain from the growing love for animals.

IDEXX (IDXX) Gains Traction From Solid CAG, Global Strength

by Zacks Equity Research

IDEXX (IDXX) consistently benefits from strong organic growth, driven by robust sales at the CAG business, fueled by a firm global Catalyst adoption.

Urmimala Biswas headshot

Near-Term Outlook for Medical Instruments Industry Bleak

by Urmimala Biswas

Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Why Is Idexx (IDXX) Up 3% Since Last Earnings Report?

by Zacks Equity Research

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

by Zacks Equity Research

IDEXX (IDXX) registers strong revenue growth on the back of CAG Diagnostics.

Moving Average Crossover Alert: IDEXX Laboratories

by Zacks Equity Research

IDEXX Laboratories is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Idexx Laboratories (IDXX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 12.50% and 0.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up

by Zacks Equity Research

Strong sales at the CAG business favor IDEXX's (IDXX) top line in Q1.

Can Steady CAG Growth Drive IDEXX's (IDXX) Q1 Earnings?

by Zacks Equity Research

Idexx (IDXX) is expected to continue reporting solid revenue growth on robust CAG performance.

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

by Zacks Equity Research

The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.

Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3

by Zacks Equity Research

Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

A diversified product portfolio and strong Dental business prospects provide Patterson Companies (PDCO) a competitive edge in the MedTech space.

Here's Why You Should Invest in Integer Holdings (ITGR) Stock

by Zacks Equity Research

Integer Holdings (ITGR) is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q4

by Zacks Equity Research

HealthEquity (HQY) witnesses strong HSA member growth in the fourth quarter of fiscal 2019.

Allscripts Partners With Opargo to Boost Practice Management

by Zacks Equity Research

Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.

Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg

by Zacks Equity Research

Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.

Allscripts Strengthens Strategic Relationship with Pulse8

by Zacks Equity Research

Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.

Here's Why Investors Should Retain McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.